Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis Takeover Bid:...

    Fortis Takeover Bid: IHH, Manipal-TPG disappointed With Board Decision

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-12T11:57:19+05:30  |  Updated On 12 May 2018 11:57 AM IST
    Fortis Takeover Bid: IHH, Manipal-TPG disappointed With Board Decision

    New Delhi: After losing out to Munjal-Burman combine in the race for Fortis, Malaysia's IHH Healthcare today said it is looking to speak to the shareholders of the Indian firm even as it evaluates options for its future course of action.


    Another suitor which also lost out, Manipal-TPG consortium, also expressed disappointment over the decision of the Fortis board to go ahead with the Rs 1,800 crore offer by Munjals and Burmans stating it would be for the shareholders to decide to accept the recommendation or not.

    "We are currently evaluating all possible options, to ensure shareholders have the opportunity to realize this value. We are evaluating all possible options, and are looking to speak to shareholders to hear their thoughts," IHH Healthcare Managing Director and CEO Tan See Leng told .

    Asserting that IHH's offer was "holistic and compelling", he said it "comprehensively addresses the short-term financing needs and long-term objectives".

    He further said the company's proposal would have benefitted all Fortis stakeholders upon triggering a mandatory takeover offer outlined in its proposal.

    Fortis shareholders would also have the chance to receive the highest cash price for their shares, if they choose to exit, Leng added.

    "We hope that all Fortis shareholders can review the recommendation made by the board carefully, before making a decision," he said.

    Similarly, Manipal Education and Medical Group MD and CEO Ranjan Pai also expressed disappointment over the Fortis board's decision.

    "Manipal remains of the view that our offer proposed the most appropriate short and long-term plan for Fortis and was in the interests of all stakeholders, including shareholders," Pai said in a statement.

    The consortium's offer comprised a significant and necessary immediate investment, a clear strategic plan to fundamentally transform Fortis, as well as synergies from a combination with Manipal, he added.

    "It is now for shareholders to decide whether they will accept the board's recommendation," Pai said.

    Fortis Healthcare had announced that its board had picked the offer from Munjals-Burmans combine over four other suitors who made binding offers.

    The board decided by majority to recommend to shareholders to approve the revised offer of Hero Enterprise Investment Office-Burman Family Office (Dabur group) made on May 1 for an upfront equity infusion of Rs 800 crore at a price of Rs 167 per share through preferential allotment.

    The Munjal-Burmans further agreed to invest another Rs 1,000 crore via preferential issue of warrants priced at Rs 176 per share.

    Besides, Manipal-TPG combine and IHH Healthcare, KKR-backed Radiant Life Care had also put in binding bids for Fortis.

    The fifth bidder, Fosun Health Holdings, an arm of Fosun International, which made a non-binding proposal to invest a total of USD 350 million (over Rs 2,295 crore) at a price up to Rs 156 per share, did not revise its offer.

    Read Also: Battle For Fortis: Munjal-Burmans emerge Victorious

    compellingFortis HealthcareFortis shareholdersFosun Health HoldingsFosun InternationalHero Enterprise InvestmentholisticIHHIHH HealthcareinvestKKR backed Radiant Life CareManipal/TPG consortiumMunjal-BurmanRanjan PaiTan See Leng
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok